Issue Date: February 26, 2018
Celularity pursues placental stem cells
Celularity has officially launched with $250 million in funding to develop treatments for cancer, autoimmune disease, diabetes, and even aging, all from placenta-derived stem cells. These stem cells, unlike blood stem cells, do not need to be matched to a patient’s immune system, making them an attractive option for use in many areas of medicine, including CAR-T immunotherapy and regenerative medicine.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society